Birkirkara, Malta (CU)_ Umana Medical, a GPI Group company, has partnered with the Preventive Cardiology and Medical Prevention, Center of Cardiology at the University Medical Center Mainz and Bayer AG to conduct a clinical study known as MyoMobile study, in order to investigate the UMANA T1 Heart Monitor, which is a latest real-time remote cardiac monitoring device, in heart failure patients.
Adrian Attard Trevisan, Umana Medical Co-founder and Managing Director expressed delight over the new partnership. He said, “The team at Umana Medical is excited by the opportunity to collaborate and work side-by-side with Bayer and the expert personnel at the University Medical Center of the Johannes Gutenberg University Mainz, one of the leading academic research institutes in Germany”.
The MyoMobile study is a potential, randomized trial that examines the impact of a personalized mobile health intervention on heart failure individuals’ physical activity status. Bayer is funding the research, which is being carried out by the University Medical Center of Johannes Gutenberg University Mainz.
University Professor Dr. Philipp Wild, Head of Preventive Cardiology and Medical Prevention and Head of Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH) at the University Medical Center Mainz said, “Exercise intolerance is a major symptom in heart failure, and physical inactivity contributes significantly to disease progression in affected patients”.
Dr. Philipp Wild also explained the benefits of the app saying, “We decided to take action and develop a mobile app that individually motivates patients to adopt an active lifestyle by providing recommendations in a simple, flexible, and interactive approach. The study will contribute to a better understanding of how a personalized app-based intervention affects quality of life, cardiovascular status, exercise capacity and molecular pathways relevant for the development and progression of heart failure syndrome.”
The Mainz group combines its extensive experience in cardiovascular and systems medicine research with wearables and app development. The software was created in collaboration with IBM and a team of additional professionals from Johannes Gutenberg University Mainz. IBM, Umana Medical, and McRoberts are the technology partners who are supporting this groundbreaking endeavor by offering cutting-edge electronic devices and applications for monitoring the health and activity conditions of study participants. The UMANA T1 Heart Monitor will be utilized to track the important indicators such as heart rhythm and irregularities, blood pressure, and respiration rate in a real time remote monitoring system.
The T1 system is an Artificial Intelligence-supported telemonitoring system that utilizes a patented tattoo sensor known as Smarter Skin. Medical experts can use the technology to properly monitor patients’ vital signs without hampering their routine lives. During the pandemic, the device was effectively used by several countries to routinely observe Covid-19 positive patients from the ease of their own houses during their observation period.
